Pol Servian

Pol Servian

Auto-generated profile, based on publicly available information

Pol Servian

Department of Surgery, Universitat Pompeu Fabra, Badalona, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
JMJuan Morote
Juan Morote
NPNatàlia Picola
Natàlia Picola
JMJesús Muñoz-Rodriguez
Jesús Muñoz-Rodriguez
NPNahuel Paesano
Nahuel Paesano
XRXavier Ruiz
Xavier Ruiz
PSPol Servian
Pol Servian
Morote J, et al. World J Mens Health. 2024 Jan;42:e3. https://doi.org/10.5534/wjmh.230028

11 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JMJuan Morote
Juan Morote
ABAngel BORQUE-FERNANDO
Angel BORQUE-FERNANDO
MTMarina Triquell
Marina Triquell
ACAnna Celma
Anna Celma
LRLucas Regis
Lucas Regis
EHEnrique Trilla Herrera
Enrique Trilla Herrera
This study is a head-to-head comparison between mPSAD and MRI-PMbdex. The MRI-PMbdex was created from 2432 men with suspected PCa; this cohort comprised the development and external validation cohorts of the Barcelona MRI predictive model. Pre-biopsy 3-Tesla multiparametric MRI (mpMRI) and 2 to 4-core transrectal ultrasound (TRUS)-guided biopsies for suspicious lesions and/or 12-core TRUS systematic biopsies were scheduled. Clinically significant PCa (csPCa), defined as Gleason-based Grade Group 2 or higher, was detected in 934 men (38.4%). The area under the curve was 0.893 (95% confidence interval [CI]: 0.880–0.906) for MRI-PMbdex and 0.764 (95% CI: 0.774–0.783) for mPSAD, with p < 0.001. MRI-PMbdex showed net benefit over biopsy in all men when the probability of csPCa was greater than 2%, while mPSAD did the same when the probability of csPCa was greater than 18%. Thresholds of 13.5% for MRI-PMbdex and 0.628 ng/mL2 for mPSAD had 95% sensitivity for csPCa and presented 51.1% specificity for MRI-PMbdex and 19.6% specificity for mPSAD, with p < 0.001. MRI-PMbdex exhibited net benefit over mPSAD in men with prostate imaging report and data system (PI-RADS) <4, while neither exhibited any benefit in men with PI-RADS 5. Hence, we can conclude that MRI-PMbdex is more accurate than mPSAD for the proper selection of candidates for prostate biopsy among men with suspected PCa, with the exception of men with a PI-RAD S 5 score, for whom neither tool exhibited clinical guidance to determine the need for biopsy.

1 June 2021 in European Urology
Verified
Journal Article
Closed access
JMJuan Morote
Juan Morote
MTMarina Triquell
Marina Triquell
ABAngel BORQUE-FERNANDO
Angel BORQUE-FERNANDO
Luis Mariano EstebanLuis Mariano Esteban
Luis Mariano Esteban
ACA. Celma
A. Celma
EHEnrique Trilla Herrera
Enrique Trilla Herrera